高级检索
当前位置: 首页 > 详情页

(-)-Epicatechin regulates the resistance of lung adenocarcinoma cells to radiotherapy through the downregulation of FOXM1

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Oncology, The First People’s Hospital of Qujing, the Qujing Afliated Hospital of Kunming Medical University, Qujing 655000, Yunnan, China [2]Department of Pathology, The First People’s Hospital of Qujing, the Qujing Afliated Hospital of Kunming Medical University, Qujing 655000, Yunnan, China
出处:
ISSN:

关键词: Lung adenocarcinoma Radiotherapy resistance Cancer stem cells (-)-Epicatechin FOXM1

摘要:
Radioresistance, particularly as manifested by cancer stem cells (CSCs), is the most common reason for the failure of cancer radiotherapy. It is essential for effective radiotherapy to inhibit cancer cell stemness. Research indicates that (-)-epicatechin (EC) enhances the radiosensitivity of non-small cell lung cancer (NSCLC); however, its influence on cell stemness in lung adenocarcinoma (LUAD) resistant to radiotherapy is still not well understood. In this study, radioresistant cell lines A549R and H1299R were constructed by repeatedly irradiating A549 and H1299 cells with gradient doses of X-rays. CCK-8, cell cloning, flow cytometry, RT-qPCR, Western blot, sphere formation detection, and other methods were used for experimental exploration. This study revealed that the radioresistance of LUAD cells was related to their stemness. By inhibiting KLF4, SOX2, CD133, and ALDH1A1 expression, EC treatment increased radiosensitivity and reduced cell sphere formation. Also, FOXM1 expression was upregulated in LUAD and in radioresistant LUAD cells. Knocking down FOXM1 inhibited the stemness of radioresistant LUAD cells. Mechanistically, EC inhibited radiotherapy-resistant LUAD cell stemness by downregulating FOXM1 expression, thereby increasing radiosensitivity. In summary, our study revealed that EC inhibited radiotherapy resistance in LUAD cells through downregulating FOXM1, and it provides a theoretical framework for treating LUAD clinically.© 2025. The Society for In Vitro Biology.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 细胞生物学 4 区 发育生物学
第一作者:
第一作者机构: [1]Department of Oncology, The First People’s Hospital of Qujing, the Qujing Afliated Hospital of Kunming Medical University, Qujing 655000, Yunnan, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:92362 今日访问量:0 总访问量:782 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号